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publication. This thinking is fundamentally flawed, as science is 
an exercise of sharing. The possible short-term gain of keeping 
others from using the results will likely turn against the authors 
as their results will be deemed irreproducible and will less likely 
be built upon by others, which would create citations and grow 
the recognition of the methodology described and the reputation 
of the authors. 
Today, increasingly we use computational tools to retrieve and 
combine information. Wilson Mizner is quoted as saying “If you 
steal from one author it’s plagiarism; if you steal from many it’s 
research”. Though there is some truth to this, many research re-
sults merit re-analysis and only come to full fruition when com-
bined with others. Data-sharing and the increasing accessibility 
1  Introduction
Science that is not reported is a hobby activity. The scientific 
community thrives on sharing, interacting, and building on the 
progress reports of research groups. However, the quality of re-
porting results is not consistent, often because we do not think 
carefully about all the elements that together make up the critical 
information and should be shared. Time pressure to publish and 
inadequate quality control add to sometimes sloppy reporting. 
Leon M. Cautillo rightly warned, “The bitterness of poor qual-
ity remains long after the sweetness of meeting the schedule is 
forgotten”. 
There are still some colleagues who believe that they can 
maintain an edge over their competition and hold off others 
from using the same approach by withholding critical details in a 
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Abstract
A good experiment reported badly is worthless. Meaningful contributions to the body of science are made by sharing 
the full methodology and results so that they can be evaluated and reproduced by peers. Erroneous and incomplete 
reporting does not do justice to the resources spent on conducting the experiment and the time peers spend reading 
the article. In theory peer-review should ensure adequate reporting – in practice it does not. Many areas of biomedical 
science have developed reporting standards and checklists to support the adequate reporting of scientific efforts, but in 
vitro research still has no generally accepted criteria. It is characterized by a “Wild West” or “anything goes” attitude. 
Such a culture may undermine trust in the reproducibility of animal-free methods and thus parallel the “reproducibility 
crisis” discussed for other life science fields. The increasing data retrieval needs of computational approaches, espe-
cially “big data” and artificial intelligence, makes the reporting quality even more important to allow the scientific 
community to take full advantage of the results. 
The first priority of reporting standards is to ensure the completeness and transparency of the provided information (data 
focus). The second tier is the quality of data display that makes information digestible and easy to grasp, compare, and 
further analyze (information focus). This article summarizes a series of initiatives geared towards improving the quality 
of in vitro work and its reporting. This shall ultimately lead to Good In Vitro Reporting Standards (GIVReSt).
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
“In God we trust. 
All others must bring data.” 
W. Edwards Deming 
(1900-1993)
Professor and author
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of evidence (WoE) assessment, and risk of bias analysis, as a 
component of systematic reviews and meta-analyses. 
With the increasing use of in vitro data, these approaches 
have to adapt also to in vitro information. The different quality 
initiatives outlined below follow a “one-quality” concept for all 
elements of the in vitro information value chain: Only good (rel-
evant) cell models can be used to build meaningful tests, which 
have to be adequately described together with their results to 
allow evaluation of their value for evidence integration so as to 
achieve an outcome responding to the information need (Fig. 
1). No element of the quality chain can be weak, otherwise the 
information need is not adequately satisfied. Obviously, many 
elements overlap, first of all because some principles of quality 
assurance and quality control are universal and also apply to cell 
culture. Others differ mainly with respect to whether they are 
applied prospectively or retrospectively, e.g., whether advising 
how to design or report a test, or how to assess a test result. This 
is a two-way-street as learning experiences gained by analyzing 
scientific reports teach us how to improve reporting. Other ini-
tiatives differ more with respect to addressing regulatory needs, 
like GIVIMP2 in the context of Good Laboratory Practice. The 
regulatory use of in vitro methods has brought about the concepts 
that feed into validation (Leist et al., 2012). Again, there is a lot 
of cross-talk with reporting standards as the method definition in 
of curated datasets and literature fuels this approach (Hartung, 
2018). And the better the information is reported, the easier it 
can be retrieved and extracted. However, often evidence cannot 
be considered because of inadequate reporting. Identifying ex-
clusion criteria for the respective pieces of evidence teaches us 
about the shortcomings of reporting.
A number of initiatives are converging toward the develop-
ment of Good In Vitro Reporting Standards (GIVReSt): Good 
Cell Culture Practices (GCCP) (Coecke et al., 2005), which are 
currently being expanded to incorporate organotypic cultures, 
including microphysiological systems, as GCCP 2.0 (Pamies et 
al., 2017a, 2018; Pamies and Hartung, 2017) define minimum 
standards for cell culture and its documentation. The Guidelines 
for Transparency and Openness Promotion (TOP) of the Open 
Science Framework1 promote more transparency when publish-
ing work that may lead to better reproducibility of published 
data. The recent OECD guidance document for Good In Vitro 
Method Practices (GIVIMP)2 (Eskes et al., 2017) sets standards 
for regulatory tests under Good Laboratory Practices (GLP). 
The development of evidence-based toxicology (Hoffmann and 
Hartung, 2006; Griesinger et al., 2009; Hartung, 2009; Stephens 
et al., 2013, 2016; Hoffmann et al., 2016, 2017), as promoted 
by the Evidence-based Toxicology Collaboration3, includes 
the determination of quality, e.g., by quality appraisal, weight 
1 https://osf.io/ud578/ 
2 https://bit.ly/2KwBtOh 
3 http://www.ebtox.org 
Fig. 1: The quality chain from cell model to satisfying an information need
A number of initiatives (in blue) detailed in the text aim to quality assure and control that in vitro approaches respond adequately to 
information needs: GCCP (Good Cell Culture Practice), GIVIMP (Good In Vitro Methods Practice), P4M (Public Private Partnership for 
Performance Standards of Microphysiological Systems) and IV-CAT (In-Vitro Critical Appraisal Tool). This is also critical for the integration 
of different types of test results / evidence streams by WoE (weight of evidence), IATA (integrated approaches to testing and assessment), 
and ITS (Integrated Testing Strategies).
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focused on providing confidence that quality requirements will 
be fulfilled”. ISO 9000, clause 3.2.10, defines quality control 
(QC) as “part of quality management focused on fulfilling qual-
ity requirements”. It is the part of Good Manufacturing Practice 
(GMP) concerned with sampling, specification, and testing, 
documentation, and release procedures, which ensures that the 
necessary and relevant tests are performed and the product is re-
leased for use only after ascertaining its quality. Simply put, QA 
focuses on the process of quality, while QC focuses on the quality 
of output. Table 1 further differentiates QA and QC (see also6) for 
reports on in vitro work.
QA thus is a verification activity that verifies that you are do-
ing the right thing in the right manner, which prevents the bugs. 
QC is a validation activity that validates the product against the 
requirements, i.e., it identifies the bugs and gets them fixed. QA 
and QC share tools, including defining processes, quality audit, 
selection of tools, and training. A quality culture should be estab-
lished in which everyone feels responsible for maintaining the 
quality of the product.
An important QC tool is the quality evaluation of articles, which 
can in turn instruct which information needs to be reported to meet 
the quality criteria. A scoping review of quality scoring tools in the 
field of toxicology was carried out by EBTC (Samuel et al., 2016). 
Relevant here, seven documents addressed the methodological 
quality of in vivo and/or in vitro studies, three were aimed primari-
ly at the toxicological or environmental health communities, while 
four were aimed more broadly. Fifteen criteria for addressing the 
methodological quality of in vivo and in vitro studies were proposed 
form of a Standard Operating Protocol (SOP) is the fundamental 
basis for any method evaluation. The concepts associated with 
validation are necessarily in constant evolution as they must 
be adapted to the individual new methods (Hartung, 2007), 
use scenarios and rigor; different names have been attributed 
to these variants (e.g., qualification, fit-for-purpose validation, 
performance standards, quality management, etc.) but they all 
include critical information on method definition, reporting, and 
validation status, which cross-fertilize with GIVReSt. 
2  The principles of quality assurance 
(QA) and quality control (QC)
According to the World Health Organization (WHO), quality 
assurance is a “wide ranging concept covering all matters that 
individually or collectively influence the quality of a product”4. 
The International Organization for Standardization (ISO) devel-
oped the ISO 9000 series standards, i.e., a set of international 
standards on quality management and quality assurance devel-
oped to help organizations effectively document the elements that 
need to be implemented to maintain an efficient quality system. 
The standards, initially published in 1987, are not specific to any 
particular industry, product or service. They underwent major 
revision in 2000 and now include ISO 9000:2005 (definitions), 
ISO 9001:2008 (requirements), ISO 9004:2009 (continuous im-
provement), and ISO 9001: 2015 (risk management). ISO 90005 
defines quality assurance (QA) as “part of quality management 
4 https://www.who.int/medicines/areas/quality_safety/quality_assurance/en/  
5 https://asq.org/quality-resources/iso-9000  
6 https://reqtest.com/testing-blog/quality-assurance-vs-quality-control-differences-2/  
Tab. 1: Quality assurance versus quality control for in vitro reporting
Quality Assurance (QA) Quality Control (QC)
QA is a set of activities for ensuring quality in the processes by 
which, in our case, reports are prepared.
QA is a managerial tool, typically implemented by the laboratory 
head. The implementation of GIVReSt would be such a tool. 
QA aims to prevent defects with a focus on the process used to 
make the report. It is a proactive quality process.
The goal of QA is to improve development and processes so that 
defects do not arise when the report is being developed.  
 
Prevention of quality problems in reporting through planned and 
systematic activities including adequate documentation of the 
work to be reported.
Establish a good quality management system by training and 
supervision of all involved as well as the assessment of its 
adequacy. Periodic conformance audits of the operations of the 
system.
QC is a set of activities for ensuring quality in the report. The 
activities focus on identifying defects in the actual reports produced.
QC is a corrective tool, which can be delegated to someone 
checking report quality. The implementation of IV-CAT would be such 
a tool. 
QC aims to identify (and correct) defects in the finished report. 
Quality control, therefore, is a reactive process.
The goal of QC is to identify defects after a report is developed 
and before it is released. This can be on the side of the laboratory, 
the peer reviewer, the publisher, or the data extractor for further 
analyses.
The activities used to achieve and maintain the report quality. 
 
Finding and eliminating sources of quality problems so that 
requirements are continually met. These include guidance 
documents and checklists used by authors and journals.
Hartung et al.
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GCCP 1.0 further includes “Table 4: Details to be included in 
papers for publication in journals, using the example of mouse 
3T3 cells”. Suggested reporting features include: type of culture, 
cell/tissue type, species, origin, description, catalogue/product 
number, basic culture medium, serum, antibiotics, other addi-
tives, frequency of medium change, culture flasks for stock cells, 
culture plates for test, culture well inserts, surface coating, sub-
culture frequency, subculture split ratio, detachment solution, 
usable passage range, passage number at receipt, passage num-
ber at use, maintenance conditions, storage conditions, relevant 
standard operating procedures/guidelines, references, and further 
comments.
These lists already give us a fairly comprehensive overview of 
reporting features for traditional cell cultures. GCCP 2.0 is trying 
to complement these for stem cell-derived models and microphys-
iological systems (MPS). Stem cells require information about the 
donors similar to primary cell work, but also on reprogramming 
and maintenance of stemness, differentiation protocols, etc. The 
work with MPS requires similar documentation efforts as they 
often work with stem cells and their derivatives. MPS have the 
peculiarity that they are often cultured for prolonged periods 
of time, which might require additional documentation. Since 
MPS mimic organ functions, it is important to document which 
functions these are and how they are assessed. Organ-on-a-chip 
MPS require additional reporting, including information about the 
utilized device, such as the material it is made of and technical 
specifications, e.g., the medium flow rate in microfluidic devices, 
frequency of medium addition, nutritional support, etc.
The Pamies et al. (2017a) workshop recommends: “A 
high-quality scientific report should cover the objective of the 
work, the protocols and SOPs used, planning and experimental 
design, execution of the study, definition of the test conditions, test 
procedure, test acceptance criteria, data collection and analysis 
as well as a discussion of the outcome. The extent to which the 
study adheres to relevant standards, regulations, guidelines or 
guidance documents should be stated, along with adherence to 
safety and quality assurance procedures. This could also include 
a statement of compliance with the GCCP principles. Reports 
on cell and tissue culture work should address a minimum set 
of information that covers the origins of the cells, characteriza-
tion, maintenance, handling, and traceability of the cells, and 
the procedures used”. The respective Table 7 lists examples of 
information needs: safety information, ethical issues, species, 
strain, source, sex, age, race, number of donors, health status, 
tissue of origin, cell type(s) isolated, date of isolation, isolation 
technique, operator, supplier, informed consent, material transfer 
agreement, medical history of donor, pathogen testing, shipping 
conditions, condition of material on arrival, identification and 
authentication, and mycoplasma testing.
4  The reporting of tests 
The difference between a model and a test is of critical impor-
tance. To give an example, primary rat liver cells are a model; 
they can be cultured under various conditions. A test serves an 
in at least four of the relevant documents; eight of these 15 criteria 
are readily aligned with standard risk of bias categories: Selec-
tion bias (baseline characteristics, similarity/appropriate control 
group selection, allocation concealment, randomization); perfor-
mance bias (blinding of researchers); detection bias (blinding of 
outcome assessors); attrition bias (complete outcome data); re-
porting bias (selective outcome reporting); confounding bias (ac-
count for confounding variables); appropriate statistical methods 
(sample size determination, statistical analysis); appropriate/
controlled exposure (incl. characterization); optimal time window 
used; statement of conflict of interest / funding source; test sub-
stance / treatment details; test organism / system. These criteria can 
now be translated into reporting recommendations.
3  Good Cell Culture Practice (GCCP) and its  
relation to reporting standards
GCCP was initiated by one of the authors (T.H.) in 1996 by or-
ganizing a symposium in Berlin, Germany. In a well-documented 
process, it was developed toward a guidance document in 2005 
(Gstraunthaler and Hartung, 1999; Hartung et al., 2002; Coecke 
et al., 2005). Two workshops in 2015 (Pamies et al., 2017a, 2018) 
reopened the guidance development in order to adapt it to tech-
nical progress, especially the increasing importance of stem cells 
and bioengineering technologies that enable the establishment of 
organotypic cultures (microphysiological systems) (Marx et al., 
2016).
Fundamentally, GCCP should form the basis of in vitro re-
porting standards. As a key principle, GCCP includes needs for 
documentation “Principle 3: Documentation of the information 
necessary to track the materials and methods used, to permit the 
repetition of the work, and to enable the target audience to under-
stand and evaluate the work” (Coecke et al., 2005, referred to as 
GCCP 1.0). Though this is intended primarily for internal com-
munication, it also forms the basis for external communication, 
although usually even more information is needed for transfer of 
a method to another laboratory as the infrastructure elsewhere is 
different. 
GCCP 1.0. includes “Table 2: Examples of requirements for 
documentation concerning the origins of cells and tissues”. 
Features include: ethical and safety, species/strain, source, sex, 
age, number of donors, health status, any special pre-treatment, 
organ/tissue of origin, cell type(s) isolated, isolation technique, 
date of isolation, operator, supplier, informed consent, material 
transfer agreement, medical history, pathogen testing, shipping 
conditions, state of material on arrival, cell line identification 
and authentication, and mycoplasma testing. GCCP 1.0 also in-
cludes “Table 3: Examples of requirements for documentation 
concerning the handling, maintenance and storage of cells and 
tissues”. Features suggested for documentation are: ethical and 
safety, morphology, histopathology, purity of isolation, pheno-
type, type of culture, culture medium, feeding cycles, growth 
and survival, characteristics, initial passage number, confluency 
at subculture, subculturing details, induction of differentiation, 
identification and authentication, ageing, mycoplasma testing. 
Hartung et al.
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ii) Known uses
iii) Evaluation study
iv) Validation study
v) Regulatory use
1.12 Abbreviation and Definitions
2. Test Method Definition
2.1 Purpose of the test method
2.2 Scientific principle of the method. 
2.3 Tissue, cells or extracts utilised in the assay and  
      the species source 
2.4 Metabolic competence of the test system
2.5 Description of the experimental system exposure regime
2.6 Response and Response Measurement
2.7 Quality / Acceptance criteria:
• Experimental data (storage/archiving), indicate unit of 
measurement of the raw data, not only transformed data
• Experimental system(s) used
• Equipment used, calibration program
• Availability of internal standards (e.g., positive 
and negative controls, reference chemicals,
• Performance benchmarks
• Standards followed such as good cell 
culture practice, if relevant
• Criteria to accept or reject experimental data
• Limit of detection and limit of quan-
tification, detection range.
2.8. Known technical limitations and strengths
2.9 Other related assays that characterise the same event 
      as in 2.1
3. Data interpretation and prediction model
3.1 Assay response(s) captured in the prediction model
3.2 Data analysis
3.3 Explicit prediction model
3.4 Software name and version for algorithm/prediction  
      model generation
4. Test Method Performance
4.1 Robustness of the method
4.2 Reference chemicals/chemical libraries, rationale for their  
      selection and other available information
4.3 Performance measures/predictive capacity (if known)
4.4 Scope and limitations of the assay, if known
5. Potential Regulatory applications
5.1 Context of use
6. Bibliography
7. Supporting information
information need and follows a defined protocol, often referred 
to as a Standard Operating Protocol (SOP), which details and 
defines how the model is employed to obtain test results. 
This includes ideally:
− A definition of the scientific purpose of the method
− A description of its mechanistic basis 
− The case for its relevance 
− The protocol, including: standard operation procedures, in-
cluding a defined exposure scheme; specification of endpoints 
and endpoint measurements; derivation, expression, and inter-
pretation of results, i.e., the (preliminary) prediction model; 
and inclusion of adequate controls.
In general, SOPs, which mainly contain detailed descriptions of 
each analytical method, are essential for maintaining the same 
analytical quality over a long period of time. The procedures are 
a prerequisite for correct transfer of methods from one laborato-
ry to another. 
The contents of an SOP according to the Guidelines on Stan-
dard Operating Procedures for Clinical Chemistry7 are typically 
as follows: (1) introduction, (2) principle of method, (3) specimen 
type, collection and storage, (4) reagents, standards and control 
– preparation and storage, (5) equipment, glassware and other 
accessories, (6) detailed procedure, (7) calculations, calibration 
curve, (8) analytical reliabilities – (QC and statistical assessment), 
(9) hazardous reagents, (10) reference range and clinical inter-
pretation, (11) limitations of method (e.g., interfering substances 
and troubleshooting), (12) references, (13) date and signature of 
authorization, (14) (effective date + schedule for review).
A very comprehensive description of test methods was devel-
oped by OECD guidance document 211 (Box 1) (OECD, 2014). 
While some of this is geared toward GLP and the context of regu-
latory use, it provides a very valuable list of aspects to be reported.
Box 1 Summary of features to report  
according to OECD Guidance Document No. 211  
“Guidance Document for Describing 
Non-Guideline In Vitro Test Methods”
1. General information
1.1 Assay name (title)
1.2 Summary
1.3 Date of Method Description (MD)
1.4 MD author(s) and contact details
1.5 Date of MD update(s) and contacts
1.6 Assay developer(s)/Laboratory and contact details
1.7 Date of assay development and/or publication
1.8 Reference(s) to main scientific papers
1.9 Availability of information about the assay in relation  
      to proprietary elements
1.10 Information about the throughput of the assay
1.11 Status of method development and uses: 
i) Development status
7 http://apps.searo.who.int/PDS_DOCS/B0218.pdf  
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test, and detailed information and protocol on both model and 
assays (the test). In addition, the test method definition should 
identify quality and acceptance criteria based on reference 
compounds and detail how to accept or discard experimental 
data; (3) data interpretation and prediction model, if applicable 
as stand-alone test or in a testing battery; (4) test method per-
formance; including robustness of the method (reproducibility 
and transferability, within and between laboratories), reference 
chemicals, performance measures and predictive capacity. The 
last part is (5) potential regulatory applications. Depending on 
the intended use of the test, these criteria have different impor-
tance. If the test is intended to be used in academia with the 
aim to study plausible mechanisms, the test might have high 
readiness despite not being ready for a regulatory context (Bal-
Price et al., 2018), e.g., without sufficient data on (4) and (5). 
To better judge the relevance and quality of data produced by 
NAMs, performance standards with defined acceptance criteria 
should be identified.
The performance standard concept was first introduced as EC-
VAM’s Modular Approach (Hartung et al., 2004) and adopted 
into OECD GD34 a year later. As per OECD, “Performance 
standards are based on an adequately validated test method and 
provide a basis for evaluating the comparability of a proposed 
test method that is mechanistically and functionally similar… 
Three main elements of performance standards (1) essential 
method components; (2) list of reference substances; (3) accu-
racy and reliability performance values”. When new methods 
are developed, which are similar in performance to the validated 
methods, a larger set of chemicals, ideally avoiding the reference 
compounds, should be used for this development. Reference 
compounds then should be used to demonstrate that the test 
performance is comparable to the validated test method. The 
examples of OECD-defined performance standards for some in 
vitro tests are available8. 
The originally defined concept of performance standards 
(Hartung et al., 2004; OECD, 2005) is currently undergoing 
a revival, owing to rapid advances in biotechnology, such as 
microphysiological systems, bioprinting, and organ-on-a-chip. 
These promising but biologically complex technologies require 
reconsideration of several aspects of formal validation, and 
the definition of performance standards is part of it. The new 
technologies are much more complex and are not only designed 
to replace a given animal test. Instead, they are multipurpose 
models that allow many different tests to be set up, which com-
plicates the validation process. For example, our human Brain-
Spheres model (“mini-brains”) (Pamies et al., 2017b) can be 
used to test neurotoxicity, developmental neurotoxicity, de- and 
remyelination, and to study many different disease aspects such 
as infection, cancer, trauma, stroke, neurodegeneration, etc. We 
discussed the concept of performance standard-based validation 
in this series earlier this year (Smirnova et al., 2018, and Figure 
3 therein). 
Performance standards for complex and multipurpose in vitro 
systems such as organ-on-a-chip are going beyond “minimum 
Recently, we tried to define test-readiness criteria (Bal-Price et 
al., 2018) to support an assessment of suggested tests for consid-
eration in a regulatory context. Such an approach is meant to ren-
der the evaluation/validation of a test method more flexible. The 
idea is to score all aspects of test readiness, under the assumption 
that various applications of the test may have more or less strin-
gent requirements. For instance, a given test method may be used 
as a pre-screen to identify compounds for further evaluation. The 
requirements for specificity and robustness would be moderate 
in this case, but if a large number of compounds is to be tested, 
the assay needs to score highly for throughput. The same assay 
may also be used to predict adverse effects of a drug before it 
enters human trials. In such a case, the criteria for robustness, 
documentation, and accuracy would be much more stringent, 
while throughput is not an important criterion. Altogether, more 
than 60 scoring items for test readiness were defined and bun-
dled into 13 groups (e.g., description of the test system/model; 
the test prediction model; or the suitability for high-throughput 
applications). Guidance was also provided on which readiness 
groups would need to score highly for various types of assay 
use, and an exemplary scoring was performed for new approach 
methods (NAM) in the area of developmental neurotoxicity. The 
readiness criteria are broadly defined and may be applied to any 
toxicological field. For instance, the test methods of the EU-Tox-
Risk project (Daneshian et al., 2016) are now being evaluated 
according to this scoring scheme.
4.1  Test quality
Test quality in this context means the status of assessing the 
quality of an assay, i.e., its fitness for purpose to satisfy a certain 
information need. This assessment will change over time with 
increasing accumulated experience. As this assessment cannot 
be done every time a test is to be used, qualification procedures 
have been put into place. Arguably, the most comprehensive 
(and rigid) of these are formal validations as applied to alter-
native methods in a regulatory context. This often has been a 
decade-long process costing several hundred thousand $ per test. 
For this reason, there is a perceived need to communicate also 
less stringent but more practical indications of test quality such 
as test readiness, compliance with performance standards, and 
other steps toward validity assessment.
Readiness qualification for a test may differ depending on its 
application. Official validated OECD Test Guidelines used for 
hazard assessment follow the OECD Guidance Document 34 
(GD 34) (OECD, 2005). However, this is not always suitable 
for qualifying NAMs as these can be non-standardized tests and 
may not be transferable to other laboratories due to very specific 
equipment, e.g., chip platforms, robotic systems, and fluidics. 
Complementary to GD 34 is OECD GD 211 for non-guideline 
in vitro test methods (OECD, 2014), which proposes how to har-
monize the reporting of these new methods to assess their rele-
vance, quality, and readiness. The guidance document is divided 
into five main parts: (1) general information; (2) test method 
definition, including the purpose, rationale, intended use of the 
8 http://www.oecd.org/chemicalsafety/testing/performance-standards.htm
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of data disqualifies all experimental data as it can be abused to 
bias results. 
The data thus should be summarized and analyzed as planned 
when designing the experiment. Any statistical analysis should 
be specified in sufficient detail allowing reproduction. The 
choice of the selected statistical approaches as such, but also 
choices made in applying them, should be justified. Graphical 
representation should provide as much information as possible, 
e.g., including a measure of dispersion for summary data such 
as the mean, and be closely linked to the statistics (if any). In-
terestingly, the widely used bar chart is often not the best option 
(Krzywinski and Altman, 2014). However, graphs should not be 
overburdened with information, possibly distracting from the 
most important features. 
5.4  Publication
The TOP guidelines9, which outline a framework that over 1,000 
journals and publishers have elected to follow, has the following 
underlying principles: “While specific needs and expectations 
vary across fields, the effective use of research findings relies 
on the availability of core information about research materials, 
data, and analysis”. A workshop hosted by the Center for Open 
Science in September 2017 and subsequent discussions led to a 
position paper suggesting a standardized approach to reporting 
and a working group of journal editors and experts joining to 
develop a minimal set of reporting standards for research in the 
life sciences. This working group drew from the collective expe-
rience of journals implementing a range of different approaches 
designed to enhance reporting and reproducibility (e.g., STAR 
Methods), existing life science checklists (e.g., the Nature Re-
search reporting summary), and results of recent meta-research 
studying the efficacy of such interventions (e.g., Macleod et al., 
2017; Han et al., 2017) to devise a set of minimal expectations 
that journals could agree to ask their authors to meet.
The working group aims for three key deliverables:
− A “minimal standards” framework setting out minimal expec-
tations across four core areas of materials (including data and 
code), design, analysis, and reporting (MDAR)
− A “minimal standards” checklist intended to operationalize 
the framework by serving as an implementation tool to aid 
authors in complying with journal policies, and editors and 
reviewers in assessing reporting and compliance with policies
− An “elaboration” document or user guide providing context 
for the “minimal standards” framework and checklist
They state: “While all three outputs are intended to provide tools 
to help journals, researchers, and other stakeholders with adop-
tion of the minimal standards framework, we do not intend to be 
prescriptive about the precise mechanism of implementation, and 
we anticipate that in many cases they will be used as a yardstick 
within the context of an existing reporting system. Nevertheless, 
we hope these tools will provide a consolidated view to help raise 
reporting standards across the life sciences”. According to their 
website, draft versions of these tools are anticipated by spring 
2019. They want to work with a wider group of journals as well 
performance standards” for a new method, similar to an existing 
validated one. The purpose of the system and the engineering 
goals should be defined, and quality assurance should be pro-
vided (which will include both correlative and mechanistic vali-
dation, Hartung et al., 2013). Basically, a performance standard, 
defined by expert consensus, should meet the test purpose (“fit-
for-purpose” concept) and anchor different elements of correla-
tive and/or mechanistic validation. This can be compared to the 
point of reference concept, introduced at an ECVAM workshop 
(Hoffmann et al., 2008). The test should comply with a point of 
reference, defined by experts, rather than being compared to a 
traditional animal test.
5  The reporting of test results
5.1  Laboratory proficiency 
This is primarily relevant for regulatory applications, though it 
would actually benefit all reported scientific data. Proficiency 
refers to the training and quality assurance / control a laboratory 
and its operators have undergone to demonstrate that they are 
capable of running the given test. This might include results of 
ring trials, intra-laboratory reproducibility assessments, histori-
cal controls, assessment of reference materials, etc. While this 
is certainly not (yet) a common scientific reporting standard, 
elements of this could be encouraged. 
5.2  Test execution versus reporting
In theory, execution and reporting should be the same, in prac-
tice this is not always the case. For example, while reference to 
method papers or public protocols is a preferred way to ensure 
comprehensive reporting, any deviations from such protocols 
need to be meticulously documented. In longer studies, ex-
change of materials and machines can occur, which also may 
require reporting.
5.3  Data analysis and representation 
Appropriate data analysis and representation is not an experi-
mental aspect that only should be considered once the data 
have been obtained; it is determined to a large extent when an 
experiment is planned. Once the experimental purpose, e.g., a 
scientific hypothesis to be tested, is clearly defined, an appro-
priate experimental approach to inform the purpose or to test 
the hypothesis can be designed. The characteristics of the data, 
such as the experimental unit, the data type, and the (assumed) 
distribution, will guide various experimental features, including 
different levels of replication, number of test concentrations, and 
experimental repetitions (Lovell and Omori, 2008).
Once the data have been obtained, any deviation from the 
planned analyses needs to be considered carefully and should 
be justified. Most importantly, no data should be omitted. Exclu-
sion of aberrant data – often called outliers – can usually not be 
justified with statistical methods, but should be clearly linked to 
observations made, e.g., a handling error. Unjustified exclusion 
9 https://cos.io/our-services/top-guidelines/
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pational safety and health, poisoning, emergency response, risk 
assessment and regulations, and toxicology. Users of NLM’s 
toxicology and environmental health resources include first re-
sponders, academic researchers, students, government agencies 
(e.g., CPSC, EPA, FDA, OSHA, and NIOSH), industry, health-
care providers, and planners.
Currently, consistency in terminology to report study methods 
and findings can be low, as is being found in, e.g., the epigen-
etic literature and especially for mechanistic research with its 
variety of assays and outcomes that it investigates and attempts 
to relate into disease progression pathways (Whaley et al., in 
preparation). This presents an obstacle to identifying and orga-
nizing relevant literature, as indexing systems will not always 
keep up with or be able to accommodate researcher-generated 
synonyms for research concepts, resulting in potentially relevant 
evidence for a systematic review being missed due to the use of 
incorrect or unconventional terminology in study reports. While 
interventions to encourage the use of consistent terminology can 
be made, they are unlikely to be completely effective consider-
ing the volume of papers being published, the number of authors 
engaged in research, and the natural variation in language use 
between different research communities.
In this context, what is more achievable and of higher 
practical use in evidence retrieval is the definition of univer-
sal ontologies (Whetzel et al., 2011; Hardy et al., 2012a,b) to 
cover the concepts being used by researchers as they describe 
their research practices and study results, and the relationships 
between them. The National Center for Biomedical Ontology 
(NCBO)13 defines an ontology as “a kind of controlled vocabu-
lary of well-defined terms with specified relationships between 
those terms, capable of interpretation by both humans and com-
puters”. Rather than focusing exclusively on consistent report-
ing by researchers, ontologies allow research data to be labeled 
and mapped onto a set of ontological concepts as a universal 
meta-language describing day-to-day research practices. This 
provides a structure for organizing, cataloguing, and retrieving 
data from the literature, which can be created by groups such 
as GCCP and applied on top of the literature rather than relying 
on individual researchers to address issues regarding, e.g., com-
mon use of terminology, by themselves on a case-by-case basis. 
Readier identification of when different researchers are investi-
gating the same (or related) things, even though they are using 
different terminology in describing what they are doing and 
may be unaware of those similarities or relations themselves, 
improves rates of retrieval of relevant evidence from literature 
databases and provides additional opportunities for synthesizing 
comparable studies in understanding health impacts of exposure 
to chemical substances.
A classic, long-running example of addressing a number of 
aspects of the ontology challenge is PubMed. The taxonomy in 
PubMed is in the process of adapting MeSH terms for toxicol-
as funders, institutions, and researchers to gather feedback and 
seek consensus towards defining and applying these minimal 
standards. As part of this feedback stage, a “community pilot” 
involving interested journals to test application of the tools shall 
be conducted. The “minimal standards” working group includes 
Karen Chambers (Wiley), Andy Collings (eLife), Chris Graf 
(Wiley), Veronique Kiermer (Public Library of Science), David 
Mellor (Center for Open Science), Malcolm Macleod (University 
of Edinburgh), Sowmya Swaminathan (Nature Research/Spring-
er Nature), Deborah Sweet (Cell Press/Elsevier), and Valda 
Vinson (Science/AAAS). Veronique Kiermer (vkiermer@plos. 
org) and Sowmya Swaminathan (s.swaminathan@us.nature.com) 
are given as contacts for interested parties.
5.5  Peer-review versus reporting
In vitro studies are becoming an increasingly important source 
of data in chemical risk assessment. There are concerns, how-
ever, about the methodological quality of these studies, and 
multiple initiatives are being undertaken to improve this. These 
initiatives to improve study quality focus on three target groups: 
(1) researchers designing, conducting and reporting primary in 
vitro exposure studies, (2) peer reviewers of journals advising 
on whether to publish a submitted manuscript, and (3) authors of 
systematic reviews aiming to assess the risk of bias/study quality 
of the primary in vitro studies included in their review. The Evi-
dence-based Toxicology Collaboration is currently conducting a 
project, led by Paul Whaley and Rob de Vries, aimed at develop-
ing a tool specifically targeted at the second group, peer review-
ers. The objective of this tool, called IV-CAT (In-Vitro Critical 
Appraisal Tool; de Vries and Whaley, 2018), is to help ensure 
comprehensive and exacting peer-review of in vitro toxicology 
studies to increase the quality (understood as “fitness-for-pur-
pose”) of published in vitro research. Completeness of reporting 
will be an important criterion within IV-CAT, but publishability 
also depends on, e.g., the scientific importance of the study and 
its internal validity. 
The development of IV-CAT will consist of five steps, which 
are extensively described in a prespecified protocol10. The first 
step, a systematic review of existing critical appraisal tools and 
reporting standards for in vitro research in order to collect criteria 
that should be included in IV-CAT, is currently being conducted. 
6  Reporting enabling evidence retrieval
In the United States, the National Libraries of Medicine (NLM) 
provide access to many online toxicology and environmental 
health resources, for example, LiverTox®11 and the TOXNET®12 
integrated system of many databases. The overall coverage of 
NLM’s resources includes chemicals and drugs, diseases and 
the environment, environmental health, exposure science, occu-
10 https://zenodo.org/record/1493498  
11 https://livertox.nih.gov/  
12 https://toxnet.nlm.nih.gov/  
13 https://www.bioontology.org/community/learning-about-ontologies   
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priority ranking algorithms to identify studies relevant to a given 
research question and may be used at various stages of the sys-
tematic review process: for question formulation, categorization 
of literature, de-duplication, or visualization of research results. 
These approaches hold great promise for facilitating accurate 
literature retrieval and facilitating systematic review, but in or-
der for the software to be more accurate and to be able to read 
and classify full-text articles, large literature databases such as 
NLM’s PubMed, as well as BIOSIS16 and Web of Science17 can 
make this work easier by improving the taxonomy and the on-
tologies. Publishers and journal editors can contribute by putting 
together requirements and enforcing measures for structured 
abstracts18 (i.e., an abstract with distinct, labeled sections, e.g., 
Introduction, Methods, Results, Discussion, for rapid compre-
hension) and complete data reporting including raw data. In the 
long term, structured abstracts and requirements for complete 
transparent data reporting will contribute not only to the literature 
retrieval accuracy, but also to the fidelity of the results, reproduc-
ibility, and credibility of science. 
7  Reporting enabling data integration
A major role in promoting the quality of studies can be played by 
systematic reviews. These comprehensive, structured, and trans-
parent summaries of existing evidence are already standard prac-
tice within clinical medicine, but until recently were relatively 
rare in other fields such as preclinical research and toxicology. 
Over the last years, however, the number of systematic reviews 
in these latter fields has been steadily increasing (Hoffmann et 
al., 2017; Whaley et al., 2016); where we have a rudimentary 
count of them, they are showing exponential growth (Whaley 
et al., 2016). 
Although the basic principles of systematic reviews are very 
similar for all fields of application, applying the principles to 
these new fields can generate substantial challenges. One clear 
example is the poor reporting of primary studies, which hampers 
assessment of the actual risk of bias of those studies. A standard 
step within systematic reviews is the assessment of the internal 
validity of the included studies. An experiment can be consid-
ered internally valid if the differences in results observed be-
tween the experimental groups can, apart from random error, be 
attributed to the intervention under investigation. This validity is 
threatened by certain types of bias, where systematic differences 
between experimental groups other than the intervention of in-
terest are introduced, either intentionally or unintentionally (de 
Vries et al., 2014). The risk of bias assessment within a system-
atic review tries to assess the actual risks of bias in the primary 
studies, for example the risk of selection bias due to a lack of 
proper randomization.
ogy. Currently, the toxicology medical search heading (MeSH) 
term (Toxicology [H01.158.891]) has only three sub-categories:
− Ecotoxicology [H01.158.891.211]
− Forensic Toxicology [H01.158.891.424]
− Toxicogenetics [H01.158.891.850]
In order to facilitate literature searching and retrieval of rele-
vant articles, in particular for systematic reviews, the toxicology 
taxonomy needs to be more granular and needs to include the 
ability to search for toxicology endpoints in different organisms 
(human, vertebrate animals, invertebrate animals, cell models, 
plants, etc.), organ systems (heart, liver, skin, neuro-, etc.), and 
should include mechanisms of toxicity. Toxicity endpoints need 
to be easily associated with the papers that mention them (e.g., 
following ECHAs classification system). Finally, more detailed 
indexing of the chemicals being studied would be helpful in re-
trieving appropriate articles (i.e., matching assays to chemicals 
the way it is done by PubChem14). 
To start addressing these deficiencies, NLM convened a 
workshop on April 6, 2018 on “Re-envisioning NLM’s Toxi-
cology and Environmental Health Resources” led by Drs. Pertti 
(Bert) Hakkinen and Florence Chang. EBTC participated in the 
workshop as one of the stakeholders along with EFSA, US EPA, 
US FDA, and other academic and government stakeholders. 
The goal of the workshop was to optimize NLM’s electronic 
resources in the areas of toxicology and environmental health 
by assessing and re-envisioning them to ensure that they con-
tinue to meet the changing needs of a diverse set of users. The 
purpose of the workshop was to gain critical insight from par-
ticipants to help NLM’s Toxicology and Environmental Health 
Information Program (TEHIP) ensure its continued relevance 
and to identify opportunities to enhance the types of content 
offered for the many and varied users of NLM’s toxicology and 
environmental health resources. The workshop built upon the 
insights gained from a web survey of workshop participants 
and other users of NLM toxicology and environmental health 
resources. The workshop provided insights that will be used to 
thoughtfully inform the development of the new generation of 
NLM resources for toxicology, environmental health, and other 
relevant information.
Text mining and artificial intelligence-enabled literature 
retrieval are examples of needs and opportunities as new tech-
nologies emerge and mature. There is growing interest in using 
machine learning approaches to priority rank studies and re-
duce human burden in screening literature (Cohen et al., 2006) 
when conducting systematic reviews. In addition, identifying 
addressable questions during the problem formulation phase 
of systematic review can be challenging, especially for topics 
that have a large literature base. SWIFT-Review (Howard et al., 
2016), SysRev15, DistillerSR (Matwin et al., 2010), and other 
software applications are in the process of developing various 
14 https://pubchem.ncbi.nlm.nih.gov 
15 www.sysrev.us   
16 https://www.ebsco.com/products/research-databases/biosis-previews  
17 http://wokinfo.com  
18 https://www.nlm.nih.gov/bsd/policy/structured_abstracts.html  
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8  Outcome reporting versus information needs
While this might sound trivial, any scientific report should have 
a purpose, an information need, to which the study and in conse-
quence the report or article is responding. This information need 
should be stated explicitly and also an assessment should be 
made to which extent the need has been met and what is needed 
to further approach this goal. 
9  Earlier in vitro reporting standard initiatives
There is no shortage of guidance on how to report science – 
the Equator network (Enhancing the quality and transparency 
of health research) identified 408 reporting guidelines20. They 
suggest templates and checklists with the message “your article 
is not complete until you have done all of these things”. For ex-
ample, a group of journal editors and experts in reproducibility 
and transparent reporting have been developing a framework for 
minimal reporting standards in the life sciences21. Table 2 lists 
some of the reporting guidance relevant to in vitro work (extract-
ed and modified from the NIH website22 and Wikipedia23). 
SYRCLE19, the Systematic Review Centre for Laboratory 
animal Experimentation, has been conducting and supporting 
systematic reviews in the field of preclinical research (both an-
imal and in vitro studies, e.g., Golbach et al., 2016) for nearly 
10 years. In their experience, in 80-90% of the cases it is not 
possible to assess the actual risk of bias, because crucial details 
of the design and conduct of the studies are not reported. In 
these cases, the risks of bias have to be scored as “unclear”; after 
all, the researchers might have applied measures to avoid bias, 
such as randomization and blinding, but just not reported them 
(Hooijmans et al., 2014). Moreover, if in so many cases it is not 
possible to assess the actual risk of bias, it is also not possible to 
assess the impact of potential biases, for example by conducting 
a subgroup analysis comparing studies that did and did not ran-
domize allocation.
At this point in time, it is therefore difficult to determine to 
what extent the results reported in the primary studies are over- 
or underestimations of the true effects of the experimental in-
terventions applied. Improving reporting standards is therefore 
not only important for reproducibility but also for assessing 
reliability. 
19 https://bit.ly/2Gw1yjU   
20 https://www.equator-network.org/reporting-guidelines/  
22 http://crosstalk.cell.com/blog/towards-minimal-reporting-standards-for-life-scientists  
23 https://www.nlm.nih.gov/services/research_report_guide.html  
12 https://en.wikipedia.org/wiki/IMRAD
Tab. 2: Existing reporting guidance relevant to in vitro work 
Organization / Guideline Description References 
American Medical Association Manual of Stylea 
CAAT GIVReST – Good In Vitro Reporting 
Standards initiative
Common Data Elementsb 
 
 
CoBRA – Citation of bioresources in journal 
articlesc 
 
EQUATOR – Enhancing the quality and 
transparency of health researchd
EASE – Guidelines for authors and translators  
of scientific articles to be published in Englishe
ENTREQ – Enhancing transparency in reporting 
the synthesis of qualitative researchf
FAIRsharingg (formerly Biosharing) 
 
ICMJE – International Committee of Medical 
Journal Editorsh (formerly known as the URM)
A manuscript style guide for medical science.  
Current 10th edition to be updated soon.
Ongoing project involving about 90 experts aiming to  
develop in vitro reporting standards.
Common data elements are standardized terms for  
the collection and exchange of data. This portal provides 
access to NIH-supported CDE initiatives and other resources 
for investigators developing data collection protocols.
Developed by members of the journal editors’ subgroup 
of the Bioresource Research Impact Factor (BRIF) for 
citing bioresources, such as biological samples, data, and 
databases.
Seeks to improve the quality of research (includes additional 
resources and links to other reporting guidelines).
Seeks quality reporting of all scientific literature. 
Provides a framework for reporting the synthesis of  
qualitative health research fostered by various universities.
A curated, informative, and educational resource on data and 
metadata standards, inter-related to databases and  
data policies.
Uniform requirements for manuscripts submitted to  
biomedical journals (also called the Vancouver style)
Christiansen, 2008 
Leist et al., 2010;  
this article
 
 
 
Bravo et al., 2015
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Organization / Guideline Description References 
International Congress on Peer Review and 
Biomedical Publicationi 
 
ISA-Tab – Mayfield Handbook Investigation/ 
Study/Assay (ISA) tab-delimited (TAB) format j 
 
MIAME – Minimum information about a  
microarray experimentk 
MIBBI – Minimum information for biological and 
biomedical investigationsl
OECD harmonised templates (OHTs) to report 
test resultsm 
OECD GD 211 for describing non-guideline  
in vitro test methodsn  
 
 
OECD GD on Good In Vitro Method Practices 
(GIVIMP)o  
 
 
PLOS editorial and publishing policies: Reporting 
guidelines for specific study designsp 
Principles and guidelines for reporting preclinical 
researchq, National Institutes of Health (NIH) 
 
 
SHERPAr (Securing a hybrid environment for 
research preservation and access) 
 
SRQRs – Standards for reporting qualitative 
research: a synthesis of recommendations
Structured Abstractst, National Library of  
Medicine (NLM)
TOP – Transparency and openness promotion 
(TOP), Open Science Frameworku 
 
 
TRANSPOSE – Transparency in scholarly 
publishing for open scholarship evolutionv
WAMEw: World Association of Medical Editors
Aims to improve the quality and credibility of scientific peer 
review and publication and to help advance the efficiency, 
effectiveness, and equitability of the dissemination of 
biomedical information.
A general-purpose framework with which to collect and 
communicate complex metadata (i.e., sample characteristics, 
technologies used, type of measurements made) from omics-
based experiments employing a combination of technologies.
Describes the basic data needed to enable the unambiguous 
interpretation of the results and to possibly replicate the 
experiment. 
Portal of almost 40 checklists, which can be used when 
reporting biological and biomedical science research.
Stakeholder-endorsed OHT 201 for reporting on “intermediate 
effects” being observed via in vitro assays and possibly other 
non-animal test methods (computational predictions, etc.).
Guidance document initiated by the Advisory Group on 
Molecular Screening and Toxicogenomics (EAGMST), 
operating under the Working Group of the National 
Coordinators of the Test Guidelines Programme (WNT) at the 
OECD.
Guidance document aiming to reduce the uncertainties in 
cell and tissue-based in vitro method derived predictions by 
applying all necessary good scientific, technical and quality 
practices from in vitro method development to in vitro method 
implementation for regulatory use.
PLOS requires that authors comply with field-specific 
standards for preparation and recording of data and select 
repositories appropriate to their field.
Set of principles to enhance rigor and further support 
research that is reproducible, robust, and transparent, which a 
number of journals have agreed to endorse. 
 
Develops open-access institutional repositories in universities 
and provides compliance-checking tools against publication 
bias and against excessive corporate influence on scientific 
integrity.
Guidance how to report qualitative research. 
Description of structured abstracts and how they are 
formatted for MEDLINE.
The guidelines cover eight transparency standards: citation, 
data transparency, analytic methods transparency, research 
materials transparency, design and analysis transparency, 
preregistration of studies, preregistration of analysis plans, 
replication 
Database of journal policies focusing on open peer review, 
co-reviewing, and detailed preprinting policies.
Association of editors of medical journals who seek to foster 
cooperation among and education of medical journal editors.
Rennie and Flanagin, 
2018 
 
 
 
 
Brazma et al., 2001 
 
 
 
 
 
 
 
 
Eskes et al., 2017 
 
 
 
 
 
Landis et al., 2012; 
Collins and Tabak, 
2014; Clayton and 
Collins, 2014;  
Lorsch et al., 2014
 
 
 
O’Brien et al., 2014 
Nakayama et al., 
2005
Foster and Deardorff, 
2017 
 
 
ahttps://bit.ly/1F0K2O6; bhttps://www.nlm.nih.gov/cde/index.html; chttp://www.equator-network.org/wp-content/uploads/2015/03/Cobra-check-list.pdf; dhttp://www.equator-
network.org; ewww.ease.org.uk/publications/author-guidelines-authors-and-translators/; fwww.equator-network.org/reporting-guidelines/entreq/; ghttps://fairsharing.org; 
hhttp://www.icmje.org; ihttps://peerreviewcongress.org/index.html; jhttp://www.dcc.ac.uk/resources/metadata-standards/isa-tab; khttp://fged.org/projects/miame/; lhttps://bit.
ly/1njFpnb; mhttp://www.oecd.org/ehs/templates/harmonised-templates-intermediate-effects.htm; nhttps://bit.ly/2k8PxTf; ohttps://bit.ly/2KwBtOh; phttps://journals.plos.org/
plosone/s/best-practices-in-research-reporting; qhttps://www.nih.gov/research-training/rigor-reproducibility/principles-guidelines-reporting-preclinical-research; rhttp://www.
sherpa.ac.uk; shttp://www.equator-network.org/reporting-guidelines/srqr/; thttps://www.nlm.nih.gov/bsd/policy/structured_abstracts.html; uhttps://cos.io/our-services/top-
guidelines/; vhttps://transpose-publishing.github.io; whttp://www.wame.org/index.php
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It is sometimes argued that this has mainly esthetic aspects, 
and that in theory any data display can be re-constructed, if only 
the primary data and their meta data connection is known. In 
practice, the situation is different. This becomes most obvious 
in the field of big data. The information contained therein is of-
ten only made accessible by the type of display chosen – and 
depending on this choice, the message is transferred well or not 
at all. In these fields, the type of data display has become an 
own research topic, and boundaries between data analysis and 
display are vanishing, e.g., in the computer sciences sub-field 
of immersive analytics (human user-guided data exploration in 
virtual visual environments). When dealing with the exploration 
of big data sets, the aim is often general knowledge or generally 
applicable rules. However, it is frequently neglected that such 
information can only be understood by many end-users in the 
form of examples. Thus, such exemplifications are an important 
feature of good presentation standards. This also applies to in 
vitro technologies and computational models. Example cases 
should be presented in parallel with the more general informa-
tion outcome. They provide the most immediate tool for the re-
cipient to judge the performance of a method or the implications 
of a data set. 
An important example for presentation issues of classical 
low-throughput experimental NAM is the visualization of the 
experimental conditions and the exposure scheme used to gen-
erate the data. If this is not done, important information is often 
lost, and the interpretation and understanding of the data is dras-
tically slowed or misguided. 
These few examples illustrate that there is an urgent need for 
reporting standards, focusing on the transfer of information, even 
when we reach a state where at least the data as such are made 
available in a findable, accessible, interoperable, and re-usable 
(FAIR) way (Corpas et al., 2018).
10  The CAAT In Vitro Reporting 
Standards (GIVReSt) initiative
Leist et al. (2010) published considerations on test descriptions in 
toxicology earlier in this series of articles (Hartung, 2017). These 
were later updated for some aspects (Leist et al., 2012; Schmidt 
et al., 2017). This work focused on general considerations of 
(i) which elements are required to fully define a test method, 
(ii) what are the common mistakes, and (iii) how can they be 
avoided. In parallel, a broader activity was started to compre-
hensively assemble reporting standards. Experts, coordinated by 
CAAT, assembled suggestions for such standards (Tab. 3), which 
were then presented in a satellite workshop of a SOT meeting 
to 60 scientists. They gave further input to the standards, so 
that a well-balanced collection was established and can soon 
be published. It is important to note here that the focus of this 
initiative is different from many others as compiled in Table 2. 
The first priority of reporting standards, as defined by various 
organizations, is to ensure the completeness and transparency 
of information given (data focus). This involves many technical 
aspects. For instance, for microarray or sequencing data such 
standards assure that all information can be found, is interopera-
ble, and can be linked to the relevant metadata. This applies not 
only to experimental data from NAM, but also to in silico data 
and the description of models used to derive them. Also, e.g., 
for models, the standards mainly define parameters that need to 
be described and all assumptions used for building the model to 
be listed. All these initiatives neglect to some extent a second 
level of required information: The “data display standards” of 
this tier are intended to ensure reporting in a form that makes 
information digestible and quick to grasp, compare, and further 
analyze. Thus, this level focuses less on the data itself, but more 
on the information that can be extracted from the data. 
Tab. 3: Chapter structure and responsibilities of CAAT GIVReST
Chapter no. Chapter structure Responsibilities
1 General considerations concerning the “message” of a James McKim, Francesca Caloni, Bas Blaauboer,  
 publication James Yager
2 Description of materials Rodger Curren, Tuula Heinonen, Erwin Roggen
3 Cells and tissues Joshua Harrill, Robert Chapin, Andras Dinnyes,  
  Gerhard Gstraunthaler
4 Description of methods for assessing endpoints of interest Tim Shafer, Nina Hasiwa, Pamela J. Lein
5 In silico methods / data processing Kevin Crofton, Bob Burrier, Andre Kleensang,  
  Alan Smith
6 Statistical considerations Sebastian Hoffmann, Daniel Dietrich,  
  Christoph van Thriel
7 General data presentation Marcel Leist, Mardas Daneshian, Jan Hengstler
8 Presentation of test features and characteristics   Matteo Goldoni, Rosella Alinovi, Marta Barenys,  
  Ellen Fritsche, Silvana Pinelli, Sara Tagliaferri,  
9 Special considerations concerning response dynamics Olavi Pelkonen 
 beyond general presentations 
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11  Discussion
This article makes the case for the need for in vitro reporting 
standards, tentatively named Good In Vitro Reporting Standards 
(GIVReSt). It summarizes, probably not even comprehensively, 
the activities known to and/or involving the authors. These ac-
tivities are closely linked to Good Cell Culture Practice (GCCP), 
and thus already span 22 years. Arguably, already that guidance 
includes the substance of what is needed to document in vitro 
work. The lack of application by authors, peer-reviewers, and 
publishers, however, shows that such guidance has to be deliv-
ered on a silver platter and that former dissemination activities 
were simply not sufficient.
Most progress with respect to quality advances has been in 
the regulatory field as Good Laboratory Practice is increasing-
ly applied to in vitro methods. Sure, the severity of regulatory 
decisions and the need to mutually accept test results between 
countries are strong driving forces. However, the reproducibility 
crisis (Baker, 2016; Jarvis and Williams, 2016) in science alone 
should prompt and cement such quality assurance. Along with 
our mantra “the most important omics is economics” (Meigs 
et al., 2018), this has also to be seen as an economic problem. 
Freedman et al. (2015) have estimated how this translates to 
wasted money: “the cumulative (total) prevalence of irreproduc-
ible preclinical research exceeds 50%, resulting in approximate-
ly US$28,000,000,000 (US $28B)/year spent on preclinical re-
search that is not reproducible – in the United States alone”. It is 
incredible how much research is apparently done and reported in 
a way that is not reproducible. This can only be characterized as 
students and scientists toying around and is not only a waste of 
resources: Wrong results put forward mislead other researchers 
and the society as a whole. Martin Van Buren is quoted as saying 
“It is easier to do a job right than to explain why you didn’t”. In 
this sense, we should embrace a culture of quality in how science 
is done and how it is reported. Henry Ford’s “Quality means 
doing it right when no one is looking” describes such a culture 
of quality. However, at this stage, we have to look and speak out 
loudly about the quality deficits in the life sciences and the way 
they are being reported. 
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